Journal of Surgery Concepts & Practice >
Study on preoperative radiotherapy in conversion therapy for patients with primary retroperitoneal soft tissue sarcoma difficult to resect or unresectable
Received date: 2022-09-27
Online published: 2023-01-30
Objective: To investigate the effect of preoperative radiotherapy in the patients with primary retroperitoneal soft tissue sarcoma difficult to resect or unresectable and recognize the results of radiotherapy associated with resection and the effect of treatment on prognosis. Methods: It was analyzed retrospectively with 44 cases of primary retroperitoneal soft tissue sarcoma difficult to resect or unresectable in Department of Radiation Oncology, Zhongshan Hospital from May 2017 to February 2022. Intensity modulated radiation therapy (IMRT) and helical tomotherapy (TOMO) were used to treat the patients, and the effects of conversion to resection treatment for patients with the prognosis and complications were analyzed. Results: A total of 44 cases received radiotherapy including 30 cases with IMRT and 14 cases with TOMO. The adverse events of radiotherapy were grade 1 to 2. After preoperative radiotherapy, 12 cases achieved partial response, 26 cases remained in stable condition and 6 cases progressed. There were 26 cases treated by surgical excision after radiotherapy with the rate of conversion to resection 59.1% (26/44). The 1- and 3-year survival rates of the cases were 93% and 72% respectively. Conclusions: The preoperative radiotherapy could have improve the conversion rates of resection for the patients with primary retroperitoneal soft tissue sarcoma difficult to resect or unresectable. The better postoperative survival was gotten with mild adverse events.
PAN Xiangou, ZHANG Li, HOU Jiazhou, DU Shisuo, ZENG Zhaochong, WANG Binliang . Study on preoperative radiotherapy in conversion therapy for patients with primary retroperitoneal soft tissue sarcoma difficult to resect or unresectable[J]. Journal of Surgery Concepts & Practice, 2022 , 27(06) : 530 -533 . DOI: 10.16139/j.1007-9610.2022.06.010
| [1] | Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7-33. |
| [2] | Turgeon MK, Cardona K. Retroperitoneal sarcomas: histology is everything[J]. Surg Clin North Am, 2022, 102(4):601-614. |
| [3] | Liles JS, Tzeng CW, Short JJ, et al. Retroperitoneal and intra-abdominal sarcoma[J]. Curr Probl Surg, 2009, 46(6):445-503. |
| [4] | Brennan MF, Antonescu CR, Alektiar KM, et al. Ma-nagement of soft tissue sarcoma[M]. New York: Springer, 2016:3-17. |
| [5] | Blay JY, Honoré C, Stoeckle E, et al. Surgery in refe-rence centers improves survival of sarcoma patients: a nationwide study[J]. Ann Oncol, 2019, 30(8):1407. |
| [6] | Villano AM, Vidri RJ, Vo ET, et al. National trends in treatment for retroperitoneal soft tissue sarcoma: a mo-dern appraisal of variability in therapeutic strategies[J]. Ann Surg Oncol, 2022, 29(4):2275-2285. |
| [7] | Swallow CJ, Strauss DC, Bonvalot S, et al. Management of primary retroperitoneal sarcoma(RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group[J]. Ann Surg Oncol, 2021, 28(12):7873-7888. |
| [8] | Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee[J]. Eur J Cancer, 2016, 62:132-137. |
| [9] | Delisle M, Gyorki D, Bonvalot S, et al. Landmark series: a review of landmark studies in the treatment of primary localized retroperitoneal sarcoma[J]. Ann Surg Oncol, 2022, 29(12):7297-7311. |
| [10] | Callegaro D, Raut CP, Ajayi T, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 trial (STRASS) versus off-trial (STREXIT) results[J]. Ann Surg, 2022. doi: 10.1097/SLA.0000000000005492. |
| [11] | Salerno KE. Radiation therapy for soft tissue sarcoma: indications, timing, benefits, and consequences[J]. Surg Clin North Am, 2022, 102(4):567-582. |
| [12] | Roohani S, Ehret F, Kobus M, et al. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review[J]. Radiat Oncol, 2022, 17(1):159. |
| [13] | Salerno KE, Alektiar KM, Baldini EH, et al. Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline[J]. Pract Radiat Oncol, 2021, 11(5):339-351. |
| [14] | Nussbaum DP, Rushing CN, Lane WO, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database[J]. Lancet Oncol, 2016, 17(7):966-975. |
| [15] | Seidensaal K, Kieser M, Hommertgen A, et al. Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (retro-ion): study protocol for a randomized phase Ⅱ pilot trial[J]. Trials, 2021, 22(1):134. |
| [16] | Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(10):1366-1377. |
/
| 〈 |
|
〉 |